Citadel Advisors
BEAM icon

Citadel Advisors’s Beam Therapeutics BEAM Stock Holding History

Citadel Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-528,970
Closed -$16M – 13700
2026
Q1 		$12.6M Buy
528,970
+273,260
+107% +$7.58M ﹤0.01% 2921
2025
Q4 		$7.09M Buy
+255,710
New +$6.52M ﹤0.01% 3743
2025
Q3 		– Sell
-2,337,517
Closed -$46.5M – 12767
2025
Q2 		$39.8M Sell
2,337,517
-162,830
-7% -$2.84M 0.01% 1420
2025
Q1 		$48.8M Buy
2,500,347
+438,101
+21% +$11.5M 0.01% 1162
2024
Q4 		$51.1M Buy
2,062,246
+566,051
+38% +$14.4M 0.01% 1254
2024
Q3 		$36.7M Buy
1,496,195
+727,041
+95% +$18.8M 0.01% 1505
2024
Q2 		$18M Buy
769,154
+729,641
+1,847% +$17.9M ﹤0.01% 2099
2024
Q1 		$1.31M Buy
39,513
+28,068
+245% +$874K ﹤0.01% 6384
2023
Q4 		$312K Sell
11,445
-1,165,470
-99% -$29M ﹤0.01% 9091
2023
Q3 		$28.3M Buy
1,176,915
+857,371
+268% +$23M 0.01% 1550
2023
Q2 		$10.2M Buy
319,544
+138,344
+76% +$4.49M ﹤0.01% 2648
2023
Q1 		$5.55M Buy
181,200
+51,938
+40% +$2.05M ﹤0.01% 3635
2022
Q4 		$5.06M Buy
129,262
+34,930
+37% +$1.56M ﹤0.01% 3839
2022
Q3 		$4.49M Buy
94,332
+41,000
+77% +$2.34M ﹤0.01% 4058
2022
Q2 		$2.06M Sell
53,332
-111,186
-68% -$4.42M ﹤0.01% 5485
2022
Q1 		$9.43M Buy
164,518
+83,789
+104% +$5.5M ﹤0.01% 3038
2021
Q4 		$6.43M Sell
80,729
-135,463
-63% -$11.6M ﹤0.01% 3857
2021
Q3 		$18.8M Buy
216,192
+194,580
+900% +$19.5M ﹤0.01% 2091
2021
Q2 		$2.78M Sell
21,612
-135,705
-86% -$10.8M ﹤0.01% 5787
2021
Q1 		$12.6M Buy
157,317
+147,684
+1,533% +$14M ﹤0.01% 2637
2020
Q4 		$786K Buy
+9,633
New +$474K ﹤0.01% 7289
2020
Q3 		– Sell
-27,126
Closed -$759K – 10064
2020
Q2 		$759K Sell
27,126
-59,173
-69% -$1.28M ﹤0.01% 6340
2020
Q1 		$1.55M Buy
+86,299
New +$1.88M ﹤0.01% 4554

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Citadel Advisors's BEAM Position: Q2 2026 in Review

Citadel Advisors sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 528,970 shares — an estimated $16M sold.

Citadel Advisors first reported a position in BEAM in Q1 2020 and held it in 23 quarters. The position peaked at $51.1M in Q4 2024. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Citadel Advisors reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 528,970 Beam Therapeutics shares in Q2 2026, an estimated $16M.
  • Citadel Advisors first reported a position in Beam Therapeutics in Q1 2020 and held it in 23 quarters.
  • Citadel Advisors's Beam Therapeutics position peaked at $51.1M in Q4 2024.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.